JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Underweight to Neutral.
Shell’s Upstream Success Balances Downstream Challenges In Q4, Analyst Reaffirms Potential Upside
Shell PLC's Q4 results show a mixed picture, with strong trading and production offsetting downstream and renewables weakness, says Piper Sandler analyst.